Skip to main content

Table 2 Correlations between the median expression levels of CYP19A1 mRNA and histopathologic features according to relapse

From: CYP19A1 gene expression in the peripheral blood of Brazilian women with breast cancer relapse

VariablesRelapse (n = 61)P valuesNonrelapsed (n =85) 
LowHighLowHighP values
n (%)n (%)n (%)n (%) 
Age
 ≤50 years13 (21.3)12 (19.7)0.87719 (22.4)16 (18.8)0.568
 > 51 years18 (29.5)18 (29.5) 24 (28.2)26 (30.6) 
Tobacco use
 Yes13 (21.3)10 (16.4)0.48818 (21.2)14 (16.5)0.327
 No18 (29.5)20 (32,8) 24 (28.2)29 (34.1) 
Menopausal status
 Premenopausal12 (19.7)14 (23.0)0.52920 (23.5)17 (20.0)0.574
 Postmenopausal19 (31.1)16 (26.2) 23 (27.1)25 (29.4) 
Tumor Grade
 G10 (0.0)4 (6.6)0.1093 (3.5)7 (8.2)0.395
 G226 (42.6)22 (36.1) 30 (35.3)29 (34.1) 
 G35 (8.2)4 (6.6) 9 (10.6)7 (8.2) 
N Classification
 N0-N127 (44.3)24 (39.3)0.45436 (42.4)40 (47.1)0.273
 N2-N34 (6.6)6 (9.8) 6 (7.1)3 (3.5) 
Tumor stage
 I3 (4.9)3 (4.9)0.2164 (4.7)9 (10.6)0.247
 II19 (31.1)12 (19.7) 21 (24.7)22 (25.9) 
 III9 (14.8)15 (24.6) 17 (20.0)12 (14.1) 
Molecular subtype
 Luminal A1 (1.6)2 (3.3)0.44554 (4.7)8 (9.4)0.182
 Luminal B17 (27.9)18 (29.5) 19 (22.4)22 (25.9) 
 Her2 overexpression4 (6.6)6 (9.8) 8 (9.4)5 (5.9) 
 Triple-negative9 (14.8)4 (6.6) 10 (11.8)8 (9.4) 
Estrogen receptors
 Positive22 (36.1)25 (41.0)0.25030 (35.3)18 (21.2)0.532
 Negative9 (14.8)5 (8.2) 12 (14.1)15 (17.6) 
Progesterone receptors
 Positive  Negative22 (36.1) 9 (14.8)19 (31.1) 11 (18.0)0.52527 (31.8)
15 (17.6)
29 (34.1)
14 (16.5)
0.759
HER2
 Positive  Negative5 (8.2) 26 (42.6)12 (19.7) 18 (29.5)< 0.03769 (10.6)
33 (38.8)
9 (10.6)
34 (40.0)
0.955
Histological type
 Ductal23 (37.7)23 (37.7)0.58426 (30.6)32 (37.6)0.154
 Lobular3 (4.9)1 (1.6) 1 (1.2)3 (3.5)
 Other5 (8.2)6 (9.8) 15 (17.6)8 (9.4)
Recurrence type
 Locoregional0 (0.0)24 (39.3)< 0.0001
 Distant metastasis19 (31.1)18 (29.5)